

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/851,327 10/656,068
Date Submitted: August 27, 2002		Filing Date	05/09/2001
Use as many sheets as necessary)		First Named Inventor	Robert J. LEVY et al.
Sheet 1 of 3		Group Art Unit	1645-1633
		Examiner Name	Unassigned
		Attorney Docket Number	047172-0170

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SDP	A1	WO	01/51092	A2	UNIVERSITY OF WASHINGTON	07/19/2001		
"	A2	WO	99/34831	A1	UNIVERSITY OF WASHINGTON	07/15/1999		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>o</sup>
SDP	A3	FASBENDER, et al., "Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer <i>in Vitro</i> and <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 10, pp. 6479-6489 (1997), The American Society for Biochemistry and Molecular Biology, Inc., USA	
	A4	UHLMANN, et al., "Chemical Reviews," <i>Antisense Oligonucleotides: A New Therapeutic Principle</i> , Vol. 90, Number 4, pp. 544-584 (1990), The American Chemical Society, USA	
	A5	SCHNEIDER, et al., "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide, -Sulfoxide, and -Sulfone Groups Replacing Phosphodiester Link Ages," <i>Tetrahedron Letters</i> , Vol. 31, No. 3, pp. 335-338 (1990), Pergamon Press plc, UK	
	A6	LOW, et al., "Complete amino acid sequence of bovine thymosin $\beta_4$ : A thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations," <i>Proc. Natl. Acad. Sci.</i> , Vol. 78, No. 2, pp. 1162-1166, (1981), Immunology, USA	
	A7	SAFER, et al., "Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets," <i>Proc. Natl. Acad. Sci.</i> , Vol. 87, pp. 2536-2540, (1990), Cell Biology, USA	
	A8	LOW, et al., "Thymic Hormones and Peptides," <i>Methods in Enzymology</i> , Vol. 116, pp. 248-255, (1985), Academic Press, USA	

Examiner Signature	<i>Scott D. Piche</i>	Date Considered	4/7/06
--------------------	-----------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/864,327 10/656,068
Date Submitted: August 27, 2002		Filing Date	05/09/2001
(use as many sheets as necessary)		First Named Inventor	Robert J. LEVY et al.
		Group Art Unit	1645-1633
		Examiner Name	Unassigned
Sheet	2 of 3	Attorney Docket Number	047172-0170

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SDP	A9	NACHMIAS, et al., "Small actin-binding proteins: the $\beta$ -thymosin family," <i>Cell Biology</i> , Vol. 5, pp. 56-62 (1993), Current Biology Ltd, USA	
	A10	BRADKE, et al., "The Role of Local Actin Instability in Axon Formation," <i>Science</i> , Vol. 283, pp. 1931-1934 (1999), American Association for the Advancement of Science, USA	
	A11	COOPER, et al., "Effects of Cytochalasin and Phalloidin on Actin," <i>The Journal of Cell Biology</i> , Vol. 105, pp. 1473-1478, (1987) The Rockefeller University Press, USA	
	A12	ORKIN, et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," pp. 1-49 (1995), National Institute of Health, USA	
	A13	INDAR, et al., "Current concepts in immunotherapy for the treatment of colorectal cancer," <i>J.R. Coll. Edinb.</i> , Vol. 47, pp. 458-474 (2002), The Royal College of Surgeons of Edinburgh, Great Britain	
	A14	DE KLEIJN, et al., "Biological therapy of colorectal cancer," <i>European Journal of Cancer</i> , Vol. 38, pp. 1016-1022 (2002), Pergamon Press, The Netherlands	
	A15	BEHR, et al., "Radioimmunotherapy of Small-Volume Disease of Metastatic Colorectal Cancer," <i>Cancer</i> , Vol. 94, Number 4, pp. 1373-1381 (2002), American Cancer Society, USA	
	A16	STEIN, et al., "Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma," <i>Cancer</i> , Vol. 94, Number 1, pp. 51-61 (2002), American Cancer Society, USA	
	A17	BEHR, et al., "Improved Treatment of Medullary Thyroid Cancer in a Nude Mouse Model by Combined Radioimmunotherapy: Doxorubicin Potentiates the Therapeutic Efficacy of radiolabeled Antibodies in a Radioresistant Tumor Type," <i>Cancer Research</i> , Vol. 57, pp. 5309-5319 (1997), American Association for Cancer Research, USA	
	A18	STEIN, et al., "Carcinoembryonic Antigen as a Target for Radioimmunotherapy of Human Medullary Thyroid Carcinoma: Antibody Processing, Targeting, and Experimental Therapy with <sup>131</sup> I and <sup>90</sup> Y Labeled Mabs," <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , Vol. 14, Number 1, pp. 37-47 (1999), Mary Ann Liebert, Inc., USA	
	A19	KINUYA, et al., "Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts," <i>J Cancer Res Clin Oncol</i> , Vol. 125, pp. 630-636 (1999), Springer-Verlag, Germany	
	A20	JUWEID, et al., "Phase I/II Trial of <sup>131</sup> I-MN-14 (F(ab) <sub>2</sub> Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma," <i>American Cancer Society</i> , Vol. 85, pp. 1828-1842, (1999)	
	A21	JUWEID, et al., "Prospects of Radioimmunotherapy in Epithelial Ovarian Cancer: Results with Iodine-131-Labeled Murine and Humanized MN-14 Anti-carcinoembryonic Antigen Monoclonal Antibodies <sup>1</sup> ," <i>Gynecologic Oncology</i> , Vol. 67, pp. 259-271 (1997) Article No. G0974870, Academic Press, USA	

Examiner  
Signature

*Justin D. Piche*

Date  
Considered

4/7/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/851,327 10/656,068
Date Submitted: August 27, 2002		Filing Date	05/09/2001
(use as many sheets as necessary)		First Named Inventor	Robert J. LEVY et al.
		Group Art Unit	1645 1633
		Examiner Name	Unassigned
		Attorney Docket Number	047172-0170
Sheet	3 of 3		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SDP	A22	SPILLER, et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood</i> , Vol. 91, No. 12, pp. 4738-4746 (1996), The American Society of Hematology, USA	
↓	A23	MUHLRAD, et al., "Dynamic Properties of Actin," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 16, pp. 11852-11858 (1994), The Journal of Biological Chemistry, USA	
↓	A24	WANG, et al., "Cellular Factors Mediate Cadmium-Dependent Actin Depolymerization," <i>Toxicology and Applied Pharmacology</i> , Vol. 139, pp. 115-121 (1996), Academic Press, Canada	

Examiner Signature	<i>Scott D. Prieth</i>	Date Considered	4/7/06
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.